Idorsia

Idorsia is a biopharmaceutical company whose purpose is to discover, develop, and commercialize innovative medicines to help more patients. It began operations after demerging from Actelion following Actelion's acquisition by Johnson & Johnson in 2017, when approximately 650 employees were transferred to Idorsia together with the discovery pipeline and early-stage clinical assets. The company is headquartered near Basel, Switzerland, and has a diversified and balanced portfolio covering multiple therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its portfolio includes products on or close to the market — QUVIVIQ (daridorexant) and TRYVIO/JERAYGO (aprocitentan) — and assets at various stages of clinical development.

Idorsia began its operations after demerging from Actelion following Actelion's acquisition by Johnson & Johnson in 2017. At that time, approximately 650 employees were transferred to Idorsia, together with the discovery pipeline and early-stage clinical assets. The company is headquartered near Basel, Switzerland, and aims to develop into a leading biopharmaceutical company with a strong scientific core.

A biopharmaceutical company with a strong scientific core, specialized in the discovery, development, and commercialization of innovative medicines.

• QUVIVIQ (daridorexant)

  An insomnia treatment described as a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern.

• TRYVIO/JERAYGO (aprocitentan)

  A product on or close to the market in Idorsia's portfolio.

• 2019.10.22

  Reported2019.10.22

  Idorsia reports nine-month 2019 financial results[5]Idorsia公布2019年前九个月财务业绩finanznachrichten.de

  Idorsia announced financial results for the first nine months of 2019, including US GAAP operating expenses of CHF 375 million and a net loss of CHF 352 million.

• 2019.10.22

  Reported2019.10.22

  Idorsia updates 2019 operating-expense guidance[5]Idorsia公布2019年前九个月财务业绩finanznachrichten.de

  Idorsia updated its 2019 financial guidance, stating that US GAAP operating expenses would not exceed CHF 540 million and non-GAAP operating expenses would not exceed CHF 500 million, excluding potential milestone payments.

Read more

1. 1Idorsia | Welcome to Idorsiaidorsia.com
2. 2Idorsia | About Idorsiaidorsia.com
3. 3Idorsia | About Idorsiaidorsia.com
4. 4Idorsia | Our Peopleidorsia.com
5. 5Idorsia公布2019年前九个月财务业绩finanznachrichten.de
6. 6Idorsia announces financial results for 2019 – clinical programs advanced markedly – approaching first kebenzinga.com
7. 7Idorsia Pharmaceuticals Ltd: Idorsia announces financial results for 2020 - a successful year marked by outstanding clinical datafinanznachrichten.de
8. 8Idorsia Pharmaceuticals Ltd: Idorsia announces financial results for the first quarter 2020finanznachrichten.de